Fintel on MSN

Aquestive Therapeutics (AQST) price target decreased by 14.74% to 9.18

The average one-year price target for Aquestive Therapeutics (NasdaqGM:AQST) has been revised to $9.18 / share. This is a ...
Nasdaq

Aquestive Therapeutics (AQST) Price Target Increased by 14.80% to 10.51

The average one-year price target for Aquestive Therapeutics (NasdaqGM:AQST) has been revised to $10.51 / share. This is an increase of 14.80% from the prior estimate of $9.15 dated November 7, 2025.
Zacks Investment Research on MSN

Here's why Aquestive Therapeutics (AQST) is a great 'buy the bottom' stock now

The price trend for Aquestive Therapeutics (AQST) has been bearish lately and the stock has lost 45.2% over the past week.

Assessing Aquestive Therapeutics (AQST) Valuation After FDA Flags Anaphylm Application Deficiencies

What triggered the latest move in Aquestive Therapeutics? Aquestive Therapeutics (AQST) recently updated investors after the ...
American Association of Individual Investors

Why Aquestive Therapeutics, Inc.’s (AQST) Stock Is Down 37.28%

As of Friday, January 09, Aquestive Therapeutics, Inc.’s AQST share price has dipped by 37.28%, which has investors ...

Cantor Fitzgerald Remains a Buy on Aquestive Therapeutics (AQST)

Detailed price information for Aquestive Therapeutics Inc (AQST-Q) from The Globe and Mail including charting and trades.
Nasdaq

Piper Sandler Maintains Aquestive Therapeutics (AQST) Overweight Recommendation

Fintel reports that on November 7, 2025, Piper Sandler maintained coverage of Aquestive Therapeutics (NasdaqGM:AQST) with a Overweight recommendation. As of October 30, 2025, the average one-year ...